Simmons & Simmons has advised on the flotation of Oxford BioDynamics on AIM.

The Simmons & Simmons team, led by partner Charles Mayo, advised the nominated adviser and broker Stifel Nicolaus Europe Limited on the admission of Oxford BioDynamics to AIM and the placing of 12,658,228 Ordinary Shares at 158 pence per share, giving it a market capitalisation of around £136m.

This is the latest in a series of transactions that Simmons & Simmons has advised on in the life sciences sector, having advised REX Bionics plc, Venture Life plc and NetScientific plc on their flotations and further deals as public companies. The firm also advised JP Morgan on the record-breaking Circassia IPO and subsequent placing and open offer.

Commenting on the transaction, Charles Mayo, said: ‘‘Personalised medicine is an area of immense potential for the life sciences sector. We were pleased to be able to use our sector expertise in support of Stifel as they assisted Oxford BioDynamics to take the company public.’’

The Simmons & Simmons team was led by Charles Mayo, assisted by Tim Wass and Haya Aftab and included Richard Binns (IP) and Jim McInerney (US Securities). Nick Cronkshaw and Zoe Arnautov provided input on tax matters.